STAT6 and classic Hodgkin lymphoma: However, this panel was only informative for 50% of the patients using cfDNA sources, so we extended it to a nine-gene panel including SOCS1, XPO1, STAT6, NFKBIE, TNFAIP3, PTPN1, B2M, ITPKB, and GNA13. Our team also led an observational prospective study based on cfDNA testing including 60 consecutive cHL cases treated by frontline ABVD and/or escalated BEACOPP.